Dark Mode
Hair loss, nail changes draw fresh scrutiny as GLP-1 use expands

Hair loss, nail changes draw fresh scrutiny as GLP-1 use expands

Latest news on WhatsApp أجدد الأخبار على واتساب

 

Hair and nail changes are emerging as a new area of scrutiny for people taking GLP-1-based medications, as researchers try to separate possible drug effects from the consequences of rapid weight loss and reduced food intake.

 

New multinational data presented at the European Academy of Dermatology and Venereology Congress in Vienna compared 575 GLP-1 users with 1,329 non-users living with obesity or Type 2 diabetes across France, the United States, Brazil and Mexico. Nail detachment was reported by 39 per cent of users, compared with 9 per cent of controls, while 66 per cent reported at least one nail disorder.

 

The findings are preliminary and do not prove that the medications caused the nail changes. Researchers have also noted that some participants had nail problems before treatment, making causation difficult to establish.

 

The evidence around hair loss is stronger. A 2026 meta-analysis of nine studies involving more than 4,100 GLP-1 users found a significantly higher risk of hair loss than with placebo, with an overall event rate of about 3.9 per cent. Semaglutide and tirzepatide have generated some of the strongest signals in recent studies.

 

Dermatologists say rapid weight loss may be an important part of the explanation. Losing substantial weight over a short period can trigger telogen effluvium, a temporary shedding pattern, while reduced appetite may also leave some patients short of protein and other nutrients needed for normal hair and nail growth.

 

The American Academy of Dermatology advises patients to report persistent hair or nail changes rather than stopping treatment on their own. A clinician can help determine whether the symptoms are related to weight loss, nutrition, another medication or an unrelated condition.

 

For now, the clearest signal is hair loss. Nail changes are drawing increasing attention, but the evidence remains newer and less settled.